BioCryst Pharmaceuticals | BCRX - 净收入



金融业
股票价格
USD
资产
USD 514.16M
现金及等价物
USD 335.91M
销售成本
USD 9.52M
流动资产
USD 404.35M
流动负债
USD 196.07M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -119.15M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 428.67M
市值
USD 1.89B
净收入
USD 245.85M
营业费用
USD 146.17M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.4M
贸易债权人
USD 15.83M
应收帐款人
USD 106.82M


净收入 更改 日
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Chugai Pharma JPY 115.42B 12.99B 2026-03
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
DBV Technologies USD -33.16M 8.71M 2025-09
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Neurocrine Biosciences USD 153.7M 55.8M 2025-12
Novavax USD 17.53M 219.91M 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03